Zacks Research Analysts Increase Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report issued on Monday, April 7th. Zacks Research analyst R. Department now forecasts that the company will earn ($4.28) per share for the year, up from their prior forecast of ($4.40). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.34 EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.08 EPS.

Several other equities analysts have also recently commented on AXSM. Truist Financial increased their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Robert W. Baird boosted their price target on Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. Mizuho raised their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, March 27th. Morgan Stanley increased their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Finally, Bank of America boosted their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $169.80.

Axsome Therapeutics Trading Up 4.2 %

AXSM opened at $101.67 on Wednesday. The stock has a market capitalization of $4.96 billion, a PE ratio of -16.97 and a beta of 0.88. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13. The firm’s fifty day moving average price is $120.05 and its 200 day moving average price is $101.90.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. NBC Securities Inc. purchased a new stake in shares of Axsome Therapeutics during the first quarter valued at $31,000. Raiffeisen Bank International AG purchased a new stake in Axsome Therapeutics during the fourth quarter valued at about $51,000. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter worth about $52,000. R Squared Ltd purchased a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $64,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $76,000. 81.49% of the stock is currently owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.